Isosorbide Mononitrate for Chronic Stable Coronary Artery Disease
Start with isosorbide mononitrate extended-release 30-60 mg once daily in the morning, titrating up to 120 mg daily as needed for symptom control, but recognize that long-acting nitrates should be considered second-line add-on therapy after beta-blockers and/or calcium channel blockers, not first-line monotherapy. 1, 2
Dosing and Administration
Initial dosing: Begin with 30 mg once daily (or 60 mg if symptoms are more severe) taken in the morning upon arising 2. The extended-release formulation must be swallowed whole with fluid—never chewed or crushed 2.
Titration strategy:
- After several days, increase to 120 mg once daily if needed 2
- Rarely, 240 mg daily may be required for refractory symptoms 2
- The dose-response relationship is well-established, with 25 mg, 50 mg, and 100 mg doses showing progressively greater ST-segment depression reduction (28.6%, 46%, and 63.5% respectively) 3
Critical timing consideration: Once-daily morning dosing provides 12 hours of antianginal coverage while creating a nitrate-free interval overnight 2, 4. This asymmetric dosing pattern is essential—it prevents tolerance development that occurs with continuous nitrate exposure 5, 6.
Place in Therapy
The 2024 ESC guidelines position long-acting nitrates as add-on therapy when symptoms remain inadequately controlled on beta-blockers and/or calcium channel blockers, or as part of initial treatment in properly selected patients 1. This represents a Class IIa recommendation with Level B evidence 1.
Do not use as monotherapy initially—beta-blockers or calcium channel blockers should form the foundation of antianginal therapy, with nitrates added for breakthrough symptoms.
Contraindications and Critical Drug Interactions
Absolute contraindication: Concomitant use with phosphodiesterase-5 inhibitors (sildenafil, vardenafil, tadalafil) due to severe hypotension risk 7.
Mandatory washout periods:
- Sildenafil or vardenafil: Wait ≥24 hours after last nitrate dose before PDE5 inhibitor use 7
- Tadalafil: Wait ≥48 hours due to its 17.5-hour half-life 7
- If patient requires PDE5 inhibitor, consider discontinuing long-acting nitrate therapy and using alternative antianginal agents 7
Common Adverse Effects
Headache is the predominant adverse effect, occurring in 38-57% of patients in a dose-dependent manner 2. This is why starting at lower doses is critical:
- 30 mg: 38% incidence
- 60 mg: 51% incidence
- 120 mg: 42% incidence
- 240 mg: 57% incidence 2
Key management point: Headaches are typically mild-to-moderate, improve with continued treatment, and rarely require discontinuation (only 5-8% stopped therapy) 2, 4. Starting low and titrating slowly minimizes this problem.
Dizziness occurs in 8-11% but rarely causes discontinuation (0-2%) 2.
Overall discontinuation rate is only 8% across all doses, with headache being the primary reason 2.
Tolerance Development—A Critical Pitfall
The tolerance problem is real but preventable. Continuous nitrate exposure causes loss of antianginal efficacy that cannot be overcome by dose escalation 2.
How to avoid tolerance:
- Use once-daily dosing in the morning, creating a 12-hour nitrate-free interval overnight 2, 4, 6
- This asymmetric regimen maintains efficacy without tolerance development 5, 6
- Studies show sustained efficacy at 4 and 12 hours post-dose with once-daily extended-release formulations 2, 4
Important caveat: One well-designed 6-week study showed that while 120-240 mg daily maintained superiority over placebo, lower doses (30-60 mg) eventually lost statistical significance versus placebo—not due to tolerance, but due to improved placebo group performance 4. This suggests higher doses may be needed for sustained long-term benefit.
Monitoring Parameters
Clinical monitoring:
- Frequency of anginal attacks (expect 83% reduction) 8
- Nitroglycerin consumption (expect 85.7% reduction) 8
- Exercise tolerance on treadmill testing 2, 4
- Blood pressure (monitor for hypotension, though changes are typically modest: 1.4-5.1 mmHg systolic reduction) 9
No routine laboratory monitoring is required. The drug has 100% bioavailability, minimal protein binding (5%), and pharmacokinetics are unchanged in elderly patients, renal failure, or liver cirrhosis 2, 5.
Special Considerations
Rebound phenomenon: Abrupt discontinuation during long-term treatment may exacerbate anginal symptoms 4. Taper if discontinuing after prolonged use.
Endothelial function concern: One study showed long-term ISMN treatment (1 year) impaired flow-mediated dilation in CAD patients 10. However, this must be weighed against proven symptomatic benefit and the drug's established role in guidelines 1.
Pharmacokinetics: Peak levels occur at 3-4.5 hours post-dose with extended-release formulations, half-life is approximately 5-6 hours, and only 1-2% is excreted unchanged in urine 2, 5.